Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND...
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva...
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex...
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage...
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024...
Addex’s Partner Discontinues ADX71149 development in Epilepsy Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a...
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland...
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq:...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 3.02 | 3.02 | 3.02 | 0 | 0 | DE |
| 4 | 0 | 0 | 3.02 | 3.02 | 3.02 | 2059 | 3.02 | DE |
| 12 | 0 | 0 | 3.02 | 3.02 | 3.02 | 614 | 3.02 | DE |
| 26 | 0 | 0 | 3.02 | 3.02 | 3.02 | 829 | 3.02 | DE |
| 52 | 0 | 0 | 3.02 | 3.02 | 3.02 | 1606 | 3.02 | DE |
| 156 | 0 | 0 | 3.02 | 3.02 | 3.02 | 791 | 3.02 | DE |
| 260 | 0 | 0 | 3.02 | 3.02 | 3.02 | 801 | 3.02 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
